Pathogenesis and treatment of the bone disease of multiple myeloma

Abstract

Abstract: Multiple myeloma is a plasma cell malignancy and bone disease is one of the important clinical features.The mechanisms include the increase of bone resorption and the decrease of bone formation.The progress in acknowledge of the pathophysiology of myeloma bone disease leads to the development of new targeted drugs. This article summarizes the progression of the pathogenesis and treatment of multiple myeloma bone disease.

Key words: Multip lemyeloma bone disease, Osteoclast, Osteoblast, Treatment Progress

CLC Number:

R733.3

HONG Juan, WANG Xin-hong. Pathogenesis and treatment of the bone disease of multiple myeloma[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(6): 705-709.

References

[1] Raab MS, Podar K, Breitkreutz I, et al. Multiple myeloma[J]. Lancet,2009,374(9686):324-339.
[2] Dougall WC,Glaccum M,Charrier K,et al.RANK is essential for osteoclast and lymphnode development[J].Genes Dev,1999,13(18):2412-2424.
[3] Li J, Sarosi I, Yan XQ,et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism [J]. Proc Natl Acad Sci USA, 2000,97(4):1566-1571.
[4] Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin[J].Biochem Biophys Res Commun,1998,247(3):610-615.
[5] Terpos E, Szydlo R, Apperley JF, et al.Soluble receptor activator of nuclear factor κB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index[J].Blood,2003,102(3): 1064-1069.
[6] Oyajobi BO, Franchin G, Williams PJ, et al . Dual effects of macrophage inflammatory protein-1a on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease[J].Blood,2003,102(1): 311-319.
[7] Oba Y, Lee JW, Ehrlich LA, et al.MIP-1α utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells[J].Exp Hematol,2005,33 (3) :272-278.
[8] Alsayed Y, Ngo H, Runnels J, et al.Mechanisms of regulation of CXCR4/SDF-1(CXCL12)-dependent migration and homing in multiple myeloma[J]. Blood,2007,109(7):2708-2717.
[9] Beider K, Begin M, Abraham M, et al. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth[J]. Exp Hematol,2011,39(3):282-292.
[10]Tanaka Y, Abe M, Hiasa M, et al. Myeloma cell-osteoclast interaction enhancesangiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin[J]. Clin Cancer Res,2007,13(3):816-823.
[11]Qiang YW, Barlogie B, Rudikoff S, et al.Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma[J]. Bone,2008,42 (4) :669-680.
[12]Pinzone JJ, Hall BM, Thudi NK, et al.The role of Dickkopf-1 in bone development, homeostasis,and disease[J]. Blood,2009,113(3): 517-525.
[13]Kaiser M, Mieth M, Liebisch P,et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma[J]. Eur J Haematol, 2008,80(6):490-494.
[14]Yaccoby S, Ling W, Zhan F, et al. Antibody based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo[J].Blood,2007,109(5):2106-2111.
[15]Takeuchi K, Abe M, Hiasa M, et al. Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth[J]. PLoS one ,2010,5(3): e9870.
[16]Hong JH, Yaffe MB. TAZ: a beta-catenin-like molecule that regulates mesenchymal stem cell differentiation[J]. Cell Cycle, 5(2):176-179.
[17]Giuliani N, Colla S, Morandi F, et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblastprogenitors and inhibit osteoblast formation and differentiation[J]. Blood ,2005,106(7):2472-2483.
[18]Andersen NF, Standal T, Nielsen JL, et al. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival[J]. Br J Haematol,2005,128(2):210-217.
[19]Standal T, Abildgaard N, Fagerli UM, et al. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma[J]. Blood,2007, 109(7):3024-3030.
[20]王增,卢红阳,翁琳.唑来膦酸抗肿瘤作用的临床研究进展[J].中国临床药理学与治疗学,2011,16(8): 945-950.
[21]Anderson KC. Lenalidomide and thalidomide: mechanisms of action-similarities and differences [J].Semin Hematol,2005,42(4 Suppl 4):S3-8.
[22]Breitkreutz I, Raab MS, Vallet S, et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma[J]. Leukemia,2008,22(10):1925-1932.
[23]Guglielmelli T, Bringhen S, Rrodhe S, et al.Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients[J]. Eur J Cancer,2011,47(6):814-818.
[24]Markovlna S,Callander NS,OConnor SL,et al.Bortezomib-Resistant nuclear factor-kappaB Activity in Multiple myeloma cells[J].Mol Cancer Res,2008,6(8):1356-1364.
[25]Vadhan-Raj S, von Moos R, Fallowfield LJ, et al.Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid[J].Ann Oncol,2012,23(12): 560-566.
[26]Rossi JF. Phase I study of atacicept in relapsed/refractory multiple myeloma or active Waldenstro¨m's macroglobulinemia: a phase I study Clin Lymphoma Myeloma[J].Leuk ,2011,11(1):136-138.
[27]Fulciniti M, Tassone P, Hideshima T, et al. Anti DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma[J].Blood,2009,114(2):371-379.
[28]Heath DJ, Chantry AD, Buckle CH, et al.Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma[J]. J Bone Miner Res , 2009, 24(3):425-436.
[29]Shain KH, Yarde DN, Meads MB, et al. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation[J]. Cancer Res,2009, 69(3): 1009-1015.
[30]Kim K, Kong SY, Fulciniti M, et al. Peter BurgerBlockade of the MEK/ERK signaling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic antimyeloma activity in vitro and in vivo[J]. Br J Haematol, 2010, 149(4): 537-549.